Trending...
- Creative Investment Research Analysis Finds Slower GDP Growth, Rising Inflation
- Tru by Hilton El Paso Airport Opens to Guests
- J&J Exterminating Celebrates 65th Anniversary and Unveils Strategic Vision at Annual Team Meeting
WATERTOWN, Mass., June 18, 2024 ~ Remix Therapeutics, a clinical-stage biotechnology company, has recently announced the appointment of Dr. Maria Koehler as an independent director to their Board of Directors. This move comes as Remix continues to develop small molecule therapies that target RNA processing and address the underlying causes of various diseases.
According to Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, Dr. Koehler's extensive industry knowledge and experience will be invaluable as the company advances its pipeline of RNA processing modulators. This includes their lead program REM-422, which is a first-in-class therapy.
Dr. Koehler brings over 20 years of experience in leading clinical and regulatory strategy operations for biotech and pharmaceutical companies focused on oncology research and development. She currently serves as the Chief Medical Officer at Repare Therapeutics, a clinical-stage precision oncology company. In addition, she has held executive and medical leadership roles at Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline.
More on The PennZone
Dr. Koehler's expertise also extends to academia, where she has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and as the director of the Bone Marrow Transplant Program at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician with an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Currently serving as an independent director on the boards of Ikena Oncology and Abdera Therapeutics, Dr. Koehler expressed her excitement about joining Remix during this pivotal time for the company. She believes that their innovative approach to reprogramming RNA processing holds great therapeutic potential and looks forward to working with Remix leadership and fellow board members to drive this science forward.
With Dr. Koehler's appointment, Remix is poised for success as they continue to make strides in developing groundbreaking therapies that target RNA processing. The company is confident that her expertise and guidance will be instrumental in their journey towards improving the lives of patients with various diseases.
According to Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, Dr. Koehler's extensive industry knowledge and experience will be invaluable as the company advances its pipeline of RNA processing modulators. This includes their lead program REM-422, which is a first-in-class therapy.
Dr. Koehler brings over 20 years of experience in leading clinical and regulatory strategy operations for biotech and pharmaceutical companies focused on oncology research and development. She currently serves as the Chief Medical Officer at Repare Therapeutics, a clinical-stage precision oncology company. In addition, she has held executive and medical leadership roles at Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline.
More on The PennZone
- Fourth Annual Free Training Day Mid-Atlantic Returns Sept. 19, 2026
- Las Vegas Headliner Don Barnhart Brings National Touring Comedy Show to Comedy Cabana
- Nevada Boxing Hall of Fame Announces 14th Annual Induction Gala Weekend Honoring Classes of 2025 and 2026
- Brosix Celebrates 20 Years of Private Team Messaging for Small and Mid-Sized Businesses
- Top 15 Mosquito-Infested Cities in Louisiana and East Texas Ranked for 2026 Mosquito Season
Dr. Koehler's expertise also extends to academia, where she has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and as the director of the Bone Marrow Transplant Program at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician with an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Currently serving as an independent director on the boards of Ikena Oncology and Abdera Therapeutics, Dr. Koehler expressed her excitement about joining Remix during this pivotal time for the company. She believes that their innovative approach to reprogramming RNA processing holds great therapeutic potential and looks forward to working with Remix leadership and fellow board members to drive this science forward.
With Dr. Koehler's appointment, Remix is poised for success as they continue to make strides in developing groundbreaking therapies that target RNA processing. The company is confident that her expertise and guidance will be instrumental in their journey towards improving the lives of patients with various diseases.
Filed Under: Business
0 Comments
Latest on The PennZone
- Baikal Engineers Published in ASHRAE Journal on Site-Assembled Custom AHUs
- AI Is Making It Easier for API-First Platforms to Connect, Partner, Reach Customers, and Grow Revenue Faster
- 2026 Editorial Freelancers Association Conference Focuses on Building Sustainable Careers
- Eichelberger Performing Arts Center Announces Fall 2026 Performance Lineup
- netElastic Powers LigaT's High-Performance Broadband Expansion and IPv6 Modernization in Portugal
- IWS Press Expands Best-Selling Classic Wealth Library with Seventh Book
- Raiku launches rkuSOL with Sanctum, Kamino, Loopscale and Exponent
- Greenland Mines Ltd (N A S D A Q: GRML) Advances Strategic Growth Initiatives as Critical Minerals Demand Accelerates
- Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
- $97.9 Million Q1 Revenue Growth Reinforces Transformation Into a Global AI & Digital Services Powerhouse: IQSTEL, Inc. (N A S D A Q: IQST)
- Philadelphia Scientist Roohid Parast Applies Evidence-Based Research to Elite Personal Fitness
- Boston Industrial Solutions Launches Natron® 348 UV Inkjet Ink for Epson S3200 Print Heads
- Heritage at South Brunswick Unveils Luxury Resort-Style Amenities Designed for Every Generation
- CAPHRA warns push for ASEAN vape ban ignores science
- Your Mortgage Toolbox Launches Free Mortgage Calculators That Show the Real Monthly Payment and Cash Needed to Close
- ENTOUCH Recognized on Inc.'s 2026 Best Workplaces List for the Third Year Running
- P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
- Cabinetworks Group announces recipient of 2025 Plant of the Year
- Honesdale Painters Launch Season With Act of Community Kindness
- Tuckwell Machinery Launches New Range of Woodworking Machinery